Drug intelligence / Profile preview

SP0202-IIb

Development stage: Unknown
Lead developer: Sanofi
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SP0202-IIb is a specific formulation of the 21-valent pneumococcal conjugate vaccine (PCV) candidate SP0202 (also known as GBP410). Developed through a collaboration between Sanofi and SK Bioscience, the vaccine is designed to protect against invasive pneumococcal disease and pneumonia caused by 21 different serotypes of Streptococcus pneumoniae. The vaccine utilizes a conjugate technology where bacterial capsular polysaccharides are chemically linked to a carrier protein to enhance immunogenicity, particularly in infants and toddlers. SP0202-IIb was one of several formulations evaluated in Phase II clinical trials to determine the optimal composition for advancing into Phase III global registration trials.

Other names: GBP410GBP-410GBP 410

Beyond the preview

Go deeper on SP0202-IIb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP0202-IIb.

Explore the full profile